INITIAL VISIT PACKET UNIFORM DATA SET (UDS) VERSION 4.0



Examiner's

Form D1a: Clinical Syndrome

ADRC:	PTID:	Form date:/ Visit #: initials:							
Language: 1 Englis 2 Spani	h								
INSTRUCTIONS: This form is to be completed by the clinician. For additional clarification and examples, see the UDS Coding Guidebook for Form D1a. Check only <u>one</u> box per question.									
_	 Diagnosis method—responses in this form are based on diagnosis by a: Single clinician Formal consensus panel Other (e.g., Two or more clinicians or other informal group) 								
Section 1 – Level of impairment – Unimpaired cognition/behavior, SCD, MCI/MBI, or dementia									
1 <i>A</i> 2	 Does the participant have: Unimpaired cognition (e.g., cognitive performance and functional status (i.e., CDR) judged to be unimpaired)? AND Unimpaired behavior (i.e., the participant does not exhibit behavior sufficient to diagnose MBI – see MBI section starting at Q7) or dementia due to FTLD or LBD and/or FTLD behavior and language domains=0? No (SKIP TO QUESTION 3) 1 Yes (CONTINUE TO QUESTION 2a) Note: For those with longstanding cognitive impairment that does not represent a decline from their usual functioning, consider checking Question 5b for a diagnosis of "Cognitively Impaired, Not MCI/dementia". 								
Subjec	tive Cognitive Decline								
2a.	Does the participant report 1) significant concerns about 2) no neuropsychological evidence of decline AND 3)								
2b.	As a clinician, are you confident that the subjective cogis clinically meaningful?	gnitive decline 0 No (END FORM HERE) 1 Yes (END FORM HERE)							
Demer	ntia criteria								
Participa	Requirement #1: Participant has cognitive or behavioral (neuropsychiatric) symptoms that meet all of the following criteria: Requirement #2: Participant must have impairment in one* or more of the following domains:								
usuRepAreInclthro	refere with ability to function as before at work or at all activities between a decline from previous levels of functioning not explained by delirium or major psychiatric disorder ude cognitive impairment detected and diagnosed bugh a combination of: 1) history-taking; 2) objective essment (bedside or neuropsychological testing)	 Impaired ability to acquire and remember new information Impaired reasoning and handling of complex tasks, poor judgment Impaired visuospatial abilities Impaired language functions Changes in personality, behavior, or comportment * In the event of single-domain impairment (e.g., language in PPA, behavior in bvFTD, visuospatial in posterior cortical atrophy, etc.), the participant must not fulfill criteria for MCI. 							
J. [No (CONTINUE TO QUESTION 4) 1 Yes (SKIP TO QUESTION 6a)								

naccmail@uw.edu NATIONAL ALZHEIMER'S COORDINATING CENTER naccdata.org

Participant	t ID: / / /	Visit #:						
Section	n 1 – Level of impairment	continued						
MCI cor	e clinical criteria							
Check all	criteria that apply in Q4.							
	Clinical concern about decline in cognition compared to participant's prior level of lifelong or usual cognitive function (e.g., based on input from participant, co-participant, and/or the clinician's judgment, CDR SB 0.5+, etc.) Impairment in one or more cognitive domains, compared to participant's estimated prior level of lifelong or usual cognitive function, or supported by objective longitudinal neuropsychological evidence of decline Largely preserved functional independence OR functional dependence that is not related to cognitive decline (e.g., based on clinical judgment)							
If all three criteria are checked, choose 1=Yes for Q4b. If less than 3 criteria are met, choose 0=No for Q4b. If only some of the criteria from Q4 are checked, with the exception of the third MCI criteria <u>alone</u> , consider a diagnosis of cognitively impaired, not MCI/dementia on Q5b. If <u>only</u> the third MCI criteria is met in Q4, select 0=No for Q5b.								
4b.		No (CONTINUE TO QUESTION 5) Yes (SKIP TO QUESTION 6a)						
Cogniti	vely impaired, not MCI/dementia							
impairme	ose of the "Cognitively impaired, not MCI/dementia" category is to capture those ent or decline who do not meet formal MCI criteria. applicable criteria for cognitively impaired, not MCI/dementia in Q5, using a	-						
5.								
If any of t	he criteria in Q5 are met choose 1=Yes for Q5b.							
5b.		No (SKIP TO QUESTION 7) Yes (SKIP TO QUESTION 7)						
Affecte	d Domains – Dementia and MCI							
Choose domains that are impaired at the current visit based on clinical judgment informed by clinical history and neuropsychological testing. Select one or more as Impaired; all others will default to unimpaired in the NACC database. Note on behavior changes: For patients with dementia who have behavior changes, record the presence of behavioral changes here (not in the following MBI section) by marking Q6f as Impaired and skipping the MBI section (SKIP TO Q8). For behavioral changes in								
the conte	ext of an MCI (or as an isolated) symptom, consider a diagnosis of MBI in the next							
6-	Manager	Impaired						
6a. 6b.	Memory Language	□1 □1						
6c.	Attention							
6d.	Executive							
6e.	Visuospatial	□1						
6f.	Behavioral (for participants with dementia only; see MBI for MCI participants)	□1						
6g.	Apraxia	□1						

	itinued					
Add Delevisor Liversian of (AADI) and district	······					
Mild Behavioral Impairment (MBI) core clinical criteria						
 Participant, co-participant, or clinician identifies a change in the participant's affect, motivation, thought content, behavior, or personality that is clearly different from their usual affect, motivation, thought content, behavior, or personality Symptoms have been present at least intermittently for the last six months or longer Late onset (i.e., age > ~50, unless early onset neurodegenerative syndrome is suspected) Not explained by delirium, other psychiatric disorder by DSM criteria (including recent onset, longstanding or recurrence of longstanding disorder). Symptoms interfere with at least one of these: work, interpersonal relationships, social activities Largely preserved independence in other functional abilities (no change from prior manner/level of functioning, or uses minimal aids or assistance) 						
7. Does the participant meet criteria for MBI? (If participant meets criteria for dementia an MBI diagnosis is excluded.)	ı					
MBI affected domains — <u>Select one or more</u> affected domains (Note: If "Yes" is indicated in any domain below, the participant should have a corresponding symptom checked on Form B9 — Clinician Judof Symptoms, either from among the specific symptoms denoted there, or in "other")	udgment					
No	Yes					
7a. Motivation (e.g., apathy symptoms on Form B9) \Box_0	1					
7b. Affective regulation (e.g., anxiety, irritability, depression, and/or euphoria symptoms on Form B9)	1					
7c. Impulse control (e.g., obsessions/compulsions, personality change, and/or substance abuse symptoms on Form B9)	1					
7d. Social appropriateness (e.g., disinhibition, personality change, and/or loss of empathy symptoms on Form B9)	1					
7e. Thought content/perception (e.g., delusions and/or hallucinations on Form B9)						
Section 2 – Clinical syndrome						
Section 2 – Clinical syndrome The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when approprim MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiologic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known have influenced the clinical diagnosis.	gical					
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when appropr MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally <u>without</u> reference to biomarker data (which is incorporated into the Etiologic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is kno	gical own and					
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when appropring MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiologic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No."	gical own and					
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when appropring MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiologic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known may have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No."	gical own and ON 10)					
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when appropring MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiologic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database.	gical own and ON 10)					
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when appropring MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiologic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known may have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. Proceedings of Section 2 is to assign a predominant and common and cognitive information and neuropsychiatric data. This should be done using clinical information and cognitive	gical own and ON 10)					
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when appropring MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiologic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known as have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. Province The participant with the participant and predominant syndrome as present; all others will default to Absent in the NACC database. Province The participant with the participant with the participant and predominant syndrome as present; all others will default to Absent in the NACC database. Province The participant with the participant with the participant and predominant syndrome as present; all others will default to Absent in the NACC database.	gical own and ON 10)					
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when appropring MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiologic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known where influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. Primary visual presentation (such as posterior cortical atrophy (PCA) syndrome)	gical own and ON 10)					
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when appropring MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiologic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known and have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. Primary predominant syndrome 8b. Dysexecutive predominant syndrome 8c. Primary visual presentation (such as posterior cortical atrophy (PCA) syndrome) 8d. Primary progressive aphasia (PPA) syndrome: Semantic PPA	gical own and ON 10)					
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when approprom MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiologic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. Primary cisual presentation (such as posterior cortical atrophy (PCA) syndrome) 8c. Primary progressive aphasia (PPA) syndrome: 8d1. If present, select one: 1 Semantic PPA 2 Logopenic PPA 3 Nonfluent/agrammatic PPA 4 Primary progressive apraxia of speech 5 PPA other/not otherwise specified 8e. Behavioral variant frontotemporal (bvFTD) syndrome 8f. Lewy body syndrome	gical own and ON 10)					
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when appropr MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiologic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known was influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome [for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. Primary cisual presentation (such as posterior cortical atrophy (PCA) syndrome) 8c. Primary visual presentation (such as posterior cortical atrophy (PCA) syndrome) 8d. Primary progressive aphasia (PPA) syndrome: 8d1. If present, select one: 1 Semantic PPA 2 Logopenic PPA 3 Nonfluent/agrammatic PPA 4 Primary progressive apraxia of speech 5 PPA other/not otherwise specified 8e. Behavioral variant frontotemporal (bvFTD) syndrome	gical own and ON 10)					

____ Form date: ____ / ___ / ___ / ___ ___ Visit #:

Participant ID:

Sec	tion 2	2 – Clinical syndrome					C	ontinued	
								Present	
8	Sh. Pr	imary supranuclear palsy (PSP) syndrome						□ 1	
	8h1. If present, select one: 1 Richardson's syndrome criteria 2 Non-Richardson's								
	8i. Tr								
	8j. Corticobasal syndrome (CBS)							□ 1	
8	8k. Multiple system atrophy (MSA) syndrome							1	
8k1. If present, select one: 1 MSA-predominant cerebellar ataxia (MSA-C) 2 MSA-predominant Parkinsonism (MSA-P) 3 MSA-predominant dysautonomia									
	81. O	ther (SPECIFY):	<u> </u>					□ 1	
9.		ate the source(s) of information used to assign the cli t one or more as Yes ; all others will default to No in th	•						
								Yes	
9	a. Cl	inical information (history, CDR)						□ 1	
9	b. Co	ognitive testing						□ 1	
9c. Biomarkers (MRI, PET, CSF, plasma)								□ 1	
Sect	ion 3	S – Primary or contributing non-neuro	degene	rative	or non-	CVD conditi	ions		
Section 3 – Primary or contributing non-neurodegenerative or non-CVD conditions The purpose of Section 3 is to identify conditions or disorders that are present and potentially contributing to the clinical sy. This must be filled out for those with cognitive or behavioral impairment (i.e., MCI, MBI, dementia, etc.) Indicate whether a groundition is a primary, contributing, or non-contributing cause of the observed impairment, based on the clinician's best judge.					given				
Select one or more condition(s) as Present ; if there are no primary or contributing non-neurodegenerative or non-CVD condition leave all conditions blank. All conditions left blank will default to Absent in the NACC database. <i>Only one diagnosis should be sele as</i> 1 = Primary.									
*In order to diagnose a disorder, DSM-5-TR criteria require that symptoms cause clinically significant distress or impairmer social, occupational, or other important areas of functioning. For more guidance see the UDS Coding Guidebook , Form D1 :									
		Condition	Present		Primary	Contributing	Non-co	ontributing	
10.	Major	depressive disorder (DSM-5-TR criteria*)		10a.	<u> </u>	\square_2		<u></u> 3	
11.	Other	specified depressive disorder (DSM-5-TR criteria*)	□ 1	11a.	1	\square_2		□ 3	
12.	Bipola	ar disorder (DSM-5-TR criteria*)	□ 1	12a.	1	2		<u></u> 3	
13.		Schizophrenia or other psychotic disorder (DSM-5-TR					□ 3		
14.	Anxiety disorder (DSM-5-TR criteria*)						<u></u> 3		
	lf	present, (SPECIFY) (check all that apply):							
	14b.	☐ 1 Generalized anxiety disorder							
	14c.	1 Panic disorder							
	14d.	1 Obsessive-compulsive disorder (OCD)							
	14e.	1 Other (SPECIFY):							
15.	Post-t	raumatic stress disorder (PTSD)(DSM-5-TR criteria*)		15a.	□ 1	□ 2		□ 3	

Form date: ____ / ___ / ___ __ __ __

Visit #:

Participant ID: ___

Participant ID:	Form date:	/	/	Visit #:	
מו נוכוף מוזנ וט.	i oiiii date.	/	/	V 131L #.	

Section 3 – Primary or contributing non-degenerative or non-CVD conditions continued							
		Condition	Present		Primary	Contributing	Non-contributing
16.	Developmental neuropsychiatric disorders (e.g., autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), dyslexia)		□ 1	16a.	□ 1	\square_2	<u></u> 3
17.	Deliriu	um (DSM-5-TR criteria*)	□ 1	17a.	1	<u></u>	3
18.	Other	psychiatric disorder (DSM-5-TR criteria*)	□ 1	18a.	□ 1	\square_2	3
	18b.	If present, (SPECIFY) :					
19.	(Distin	natic brain injury nct from TES and CTE, which are documented as a al Syndrome and Etiologic Diagnosis, respectively)	□ 1	19a.	□ 1	\square_2	□ ₃
20.	Epilep	osy	1	20a.	□ 1	2	3
21.	Norm	al-pressure hydrocephalus	□ 1	21a.	1	<u></u>	3
22.	CNS N	leoplasm	□ 1	22a.	□ 1	\square_2	3
22		present, select one: 1 Benign 2 Malignant					
23.	Huma	n immunodeficiency virus (HIV) infection	1	23a.	□ 1	\square_2	3
24.	Post C	OVID-19 cognitive impairment	□ 1	24a.	□ 1	\square_2	3
25.	Sleep apnea)	apnea (i.e., obstructive, central, mixed or complex sleep		25a.	□ 1	<u></u>	□3
26.	infect	tive impairment due to other neurologic, genetic, ious conditions (<i>not listed above</i>), or systemic se/medical illness (as indicated on Form A5/D2)	□ 1	26a.	□1	<u>2</u>	3
26	ib. If p	oresent, (SPECIFY):					
27.	Cogni	tive impairment due to alcohol use or abuse	□ ₁	27a.	□ ₁	_2	3
28.	Cogni	tive impairment due to substance use or abuse	□ ₁	28a.	□ ₁	\square_2	3
29.	Cogni	tive impairment due to medications	□ ₁	29a.	□ ₁	\square_2	3
30.	Cogni	tive impairment not otherwise specified (NOS)	□ ₁	30a.	□ ₁	\square_2	3
30	b. If	oresent, (SPECIFY):					
31.	Cogni	tive impairment not otherwise specified (NOS)	1	31a.	□ 1	\square_2	3
31	b. If	present, (SPECIFY):					
32.	Cogni	tive impairment not otherwise specified (NOS)	1	32a.	□ 1	\square_2	3
32	h If	present (SDECIEV).					